To assess if Nr5a2 is a mediator of mutant p53 transcriptional rewiring in human breast cancers, we performed gene expression analyses of the METABRIC consortium, a highly annotated and comprehensive omics analysis of breast cancers (47). The gene discussed is TP53; the disease is breast carcinoma.